Incepta launches ‘Linatab E’ for diabetic patients
Incepta Pharmaceuticals has launched a new medicine under the brand name of "Linatab E'' that combines Linagliptin and Empagliflozin, the two most remarkable and safe therapeutic classes of modern times for controlling diabetes.
National Professor AK Azad Khan unveiled the medicine at the Bangladesh Institute of Health Science in Darus Salam of Mirpur in Dhaka yesterday, a press release said.
The medicine has brought a breakthrough in diabetes management globally because it is remarkably safe for diabetic patients with cardiac disorders.
The medicine offers no chance of sudden glucose falls, a regular phenomenon in the case of diabetic patients.
Incepta released the medicine in a more affordable way for all classes of people: Linatab E 5/10 tablet at Tk 30 and Linatab E 5/25 tablet at Tk 40 only.
For the patients it will reduce the pill burden as only one tablet per day can serve the purpose as opposed to two tablets that patients are required to take.
Comments